BAUSCH HEALTH Reports Failure of RED-C Phase 3 Trials for Hepatic Encephalopathy Treatment

Bausch Health Companies Inc. (NYSE: BHC) announced on January 23, 2026, that its RED-C Phase 3 clinical trials for a treatment targeting hepatic encephalopathy did not meet the primary endpoint. The trial results, released after market hours, sent shares of Bausch Health tumbling by 15% in early trading. Analysts noted the failure represents a significant setback for the company's efforts to expand its portfolio in neurological disorders. Despite this outcome, Bausch Health stated it would continue exploring alternative pathways for the drug candidate. The company's stock closed at $12.50 per share, down from $14.70 prior to the announcement.